New drug duo aims to wipe out esophageal tumors before surgery
NCT ID NCT07627347
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving two drugs (anlotinib and bemocizumab) before surgery can improve outcomes for people with resectable esophageal squamous cell carcinoma. About 25 adults with stage II-IIIB disease will receive the combination, then undergo surgery. The main goal is to see if the drugs can eliminate all cancer cells by the time of surgery, potentially leading to better long-term survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nanfang Hospital, Southern Medical University
RECRUITINGGuangzhou, Guangdong, 510515, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two-Drug cocktail aims to shrink Hard-to-Treat esophageal and stomach tumors
- Could a drug combo let some esophageal cancer patients skip surgery?
- New drug cocktail shows promise against tough esophageal cancer
- New triple therapy hopes to outsmart tough esophageal cancer
- New hope for esophageal cancer patients who failed immunotherapy
- Could a new staging system better predict esophageal cancer outcomes?